Alembic Pharmaceuticals Ltd.

₹677.95

-25.3 (-3.6%)

APLLTD Share Price

Pharmaceuticals & Biotechnology

As on March 13, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 13,326 Cr

P/E Ratio22.84

Dividend Yield0.81 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	701.07	Bearish
10-DMA	703.61	Bearish
20-DMA	732.42	Bearish
50-DMA	768.84	Bearish
100-DMA	832.22	Bearish
200-DMA	899.6	Bearish

Historical Performance

1 Year

-18.1%

3 Years

38.8%

5 Years

-27.9%

10 Years

9.9%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	66,721	62,286	56,526	53,058	53,931
Total Expenditure	56,692	52,960	49,446	44,316	39,131
Other Income	479	290	30	505	875
Operating Profit	10,508	9,617	7,111	9,246	15,676
Interest	788	562	502	177	160
Depreciation	2,786	2,727	2,754	2,868	1,835
Profit Before Tax	7,072	6,318	3,546	6,254	13,681
Consolidated Net Profit	5,834	6,158	3,420	5,209	11,465
Adjusted EPS	30	31	17	27	58

Compounded Sales Growth

10 Years:26.5

5 Years:7.7

3 Years:4.7

TTM:1.4

Compounded Profit Growth

10 Years:15.6

5 Years:-6.8

3 Years:2.3

TTM:-1.1

Stock Price CAGR

10 Years:1

5 Years:-5.9

3 Years:11.8

TTM:-18.1

Return on Equity

10 Years:38.2

5 Years:58.3

3 Years:17.4

last year:29.7

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	393	393	393	393	393
Total Reserves	51,516	47,789	43,312	51,982	50,277
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	51	28	524	1,621	3,612
Other Current Liabilities	2,321	2,237	2,512	5,165	5,579
Short Term Borrowings	11,956	4,305	6,359	4,300	---
Total Liabilities	77,088	63,412	60,637	72,302	69,614
Capital Work in Progress	8,372	5,244	6,013	22,058	19,443
Long Term Loans & Advances	311	333	537	349	367
Currents Investments	---	---	---	---	1,870
Short Term Loans and Advances	3,425	2,890	2,546	4,369	6,982
Total Current Assets	41,897	31,438	29,139	29,748	29,044
Total Assets	77,088	63,412	60,637	72,302	69,614
Adjusted Book Value	264	245	222	266	258

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 22.84, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a moderate 3-year price CAGR of 11.8%, reflecting average market performance.
The stock carries a low beta of 0.6, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹10508 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹66721 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 824756.7

No. of Shares: 1217 (Approx)

Performance:-17.5%

P/L: ₹-175243.3

NIFTY Performance: 3.4%

1 day Top Gainers